Lasa Supergenerics Ltd
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
- Market Cap ₹ 122 Cr.
- Current Price ₹ 24.4
- High / Low ₹ 41.2 / 20.1
- Stock P/E
- Book Value ₹ 22.6
- Dividend Yield 0.00 %
- ROCE -11.9 %
- ROE -14.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.08 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -11.9% over past five years.
- Company has a low return on equity of 1.31% over last 3 years.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -10.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|
0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 117 | |
0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 106 | |
Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 11 |
OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -5% | 9% | |
0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -19 | |
Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 |
Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 12 |
Profit before tax | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -22 |
Tax % | -10% | 19% | 25% | 23% | 23% | 13% | 9% | ||
0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -21 | |
EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.27 | ||
Dividend Payout % | 0% | 0% | 0% | 0% | 4% | -24% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -12% |
3 Years: | -8% |
TTM: | -20% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 88% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 2% |
3 Years: | -27% |
1 Year: | -3% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 0% |
3 Years: | 1% |
Last Year: | -14% |
Balance Sheet
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0 | 0 | 23 | 23 | 41 | 41 | 50 | 50 | 50 |
Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 63 |
0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 1 | |
0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 52 | |
Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 166 |
0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 115 | |
CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 5 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 46 | |
Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 166 |
Cash Flows
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|
0 | -3 | 40 | 41 | 14 | 41 | 9 | -17 | |
0 | 0 | -44 | -7 | -2 | -4 | -3 | 11 | |
0 | 0 | 4 | -33 | -10 | -36 | -0 | -4 | |
Net Cash Flow | 0 | -3 | 0 | -0 | 2 | 1 | 6 | -10 |
Ratios
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | |
Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | |
Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | |
Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | |
Working Capital Days | 58 | 44 | -2 | 31 | 35 | 12 | -17 | |
ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - Certificate under regulation 74 (5) SEBI (Depositories and Participants) Regulation''s, 2018 for the quarter and the year ended March 31, 2024 received from Bigshare Services …
- Compliance Under Reg 7(3) SEBI LODR, Regulations 2015 For The Period Ended March 31, 2024 15 Apr
- Closure of Trading Window 29 Mar
- Board Meeting Outcome for Revised Outcome Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 11 Mar
- Board Meeting Outcome for Outcome Of Board Meeting 8 Mar
Annual reports
Concalls
-
Aug 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Jun 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Dec 2017Transcript PPT
Business Overview:[1]
LSL is a part of Lasa group which is a veterinary API manufacturing entity. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary APIs with one of the largest production capabilities in India. It covers entire animal and human healthcare value chain—from discovery-to-delivery, in research, manufacturing and global marketing. Company has backward integrated its key molecules—from discovery research up to full-scale bulk production